Our Services
Medical Information
Helpful Resources
Published on: 8/18/2026
Pseudofractures are not true breaks but bands of unmineralized bone that reveal softening rather than simple loss of density. They appear on imaging as Looser zones, most often along the femoral neck, pubic rami, ribs, or outer edges of long bones, and they point toward osteomalacia or conditions like vitamin D deficiency, hypophosphatemia, or renal disease. This distinction matters because thinning bone (osteoporosis) and softening bone (osteomalacia) require very different treatment paths, from vitamin D and phosphate correction to managing kidney or absorption problems. Bone pain, muscle weakness, waddling gait, and tenderness often accompany these findings, offering clues that mineralization has failed. There are several important factors to consider, so see below to understand more.
If persistent bone pain, unexplained weakness, or imaging findings suggest something beyond ordinary bone loss, a free, instant, online symptom check can help organize your symptoms, highlight patterns that point toward softening rather than thinning, and guide you toward the right next steps with a clinician.
Last reviewed for medical accuracy: 08/18/2026
Pseudofracture bone changes—also called Looser’s zones—are often mistaken for simple bone thinning. In reality, they point to bone softening (osteomalacia) rather than the classic thinning seen in osteoporosis. Understanding pseudofractures can help you and your doctor find the right cause and treatment.
Unlike true fractures, pseudofractures do not run completely through the bone cortex. Instead, they reflect areas where the bone has softened and can no longer bear normal stress.
| Feature | Osteomalacia (Softening) | Osteoporosis (Thinning) |
|---|---|---|
| Bone Quality | Poor mineralization | Adequate mineralization |
| Bone Density | May be normal or low | Reduced |
| Fracture Pattern | Pseudofractures (Looser’s zones) | Vertebral compression, wrist |
| Pain | Diffuse bone pain, muscle weakness | Often no pain until fracture |
Osteomalacia is a defect in bone mineralization due to:
Osteoporosis is a reduction in bone mass and microarchitectural deterioration.
Nutritional Deficiencies
Chronic Kidney Disease
Liver Disease
Medications
Genetic Disorders
Pseudofracture bone changes may present with:
Bone Pain
Dull, aching pain in affected regions (hips, ribs, lower back).
Muscle Weakness
Difficulty climbing stairs, rising from a chair.
Fracture Risk
Incomplete cracks can progress to full fractures under stress.
Walking Difficulties
Gait instability, limping.
If you notice persistent bone pain or weakness, you might consider a free, online symptom check, using the doctor approved Ubie Symptom Checker to help clarify your next steps.
Clinical Evaluation
Laboratory Tests
Imaging
The primary goal is to restore normal bone mineralization:
Vitamin D Supplementation
Calcium Intake
Sunlight Exposure
Kidney Disease
Liver Disease
Medication Review
Analgesics
Physical Therapy
Orthopedic Support
Pseudofractures can progress to complete breaks if untreated. Contact your doctor if you experience:
For a quick check on your symptoms, consider a free, online symptom check, using the doctor approved Ubie Symptom Checker.
Always speak to a doctor about any serious or life-threatening symptoms. If you’re unsure about your bone health or have persistent pain, a medical professional can guide you to the right tests and treatments.
(References)
* Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, Dahir KM, Nunes ME. Hypophosphatasia. 1993. PMID: 20301329.
* Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, Laurent MR, Harvengt P, Mortier GR, Böckenhauer D. X-Linked Hypophosphatemia. 1993. PMID: 22319799.
* Munoz J, Michel Ortega R, Celzo F, Donthireddy V. 'Tumour-induced osteomalacia'. BMJ Case Rep. 2012 Jun 25;2012. doi: 10.1136/bcr.03.2012.5975. Epub 2012 Jun 25. PMID: 22736784; PMCID: PMC3448346.
* Insogna KL, Briot K, Imel EA, Kamenický P, Ruppe MD, Portale AA, Weber T, Pitukcheewanont P, Cheong HI, Jan de Beur S, Imanishi Y, Ito N, Lachmann RH, Tanaka H, Perwad F, Zhang L, Chen CY, Theodore-Oklota C, Mealiffe M, San Martin J, Carpenter TO, AXLES 1 Investigators. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis. J Bone Miner Res. 2018 Aug;33(8):1383-1393. doi: 10.1002/jbmr.3475. Epub 2018 Jun 26. PMID: 29947083.
* John TJ, van der Made T, Conradie M, Coetzee A. Osteomalacia and looser zones. QJM. 2019 Jun 1;112(6):455. doi: 10.1093/qjmed/hcy293. PMID: 30590855.
* Haffner D, Emma F, Eastwood DM, Biosse Duplan M, Bacchetta J, Schnabel D, Wicart P, Bockenhauer D, Santos F, Levtchenko E, Harvengt P, Kirchhoff M, Di Rocco F, Chaussain C, Brandi ML, Savendahl L, Briot K, Kamenicky P, Rejnmark L, Linglart A. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol. 2019 Jul;15(7):435-455. doi: 10.1038/s41581-019-0152-5. PMID: 31068690; PMCID: PMC7136170.
* Haffner D, Emma F, Seefried L, Högler W, Javaid KM, Bockenhauer D, Bacchetta J, Eastwood D, Biosse Duplan M, Schnabel D, Wicart P, Ariceta G, Levtchenko E, Harvengt P, Kirchhoff M, Gardiner O, Di Rocco F, Chaussain C, Brandi ML, Savendahl L, Briot K, Kamenický P, Rejnmark L, Linglart A. Clinical practice recommendations for the diagnosis and management of X-linked hypophosphataemia. Nat Rev Nephrol. 2025 May;21(5):330-354. doi: 10.1038/s41581-024-00926-x. Epub 2025 Jan 15. PMID: 39814982.
* Seefried L, Rak D, Genest F. Grading Pseudofractures-The "Breach-Beak-Bump-Bridge" Approach. Calcif Tissue Int. 2025 Apr 16;116(1):62. doi: 10.1007/s00223-025-01371-z. Epub 2025 Apr 16. PMID: 40240537; PMCID: PMC12003480.
* Böckmann I, Haffner D. The Diagnosis and Therapy of XLH. Calcif Tissue Int. 2025 Apr 28;116(1):66. doi: 10.1007/s00223-025-01374-w. Epub 2025 Apr 28. PMID: 40295317; PMCID: PMC12037658.
* Khan AA, Rush ET, Wakeford C, Staub D, Brandi ML. Key Learnings from Clinical Research and Real-World Evidence on Asfotase Alfa Effectiveness in Hypophosphatasia: 10 Years Post-Approval. Adv Ther. 2025 Sep;42(9):4270-4299. doi: 10.1007/s12325-025-03309-1. Epub 2025 Jul 25. PMID: 40715944; PMCID: PMC12394269.
We would love to help them too.
For First Time Users
We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.
Was this page helpful?
Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.